Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

ADAM9-targeted antibody-drug conjugate

DRUG CLASS:

ADAM9-targeted antibody-drug conjugate

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

ADAM9 expression	Solid Tumor	ADAM9 expression	Solid Tumor	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2
ADAM9 expression	Gastric Cancer	ADAM9 expression	Gastric Cancer	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2
ADAM9 expression	Non Small Cell Lung Cancer	ADAM9 expression	Non Small Cell Lung Cancer	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2	IMGC936 Sensitive: C2 – Inclusion Criteria IMGC936 Sensitive : C2
ADAM9 overexpression	Triple Negative Breast Cancer	ADAM9 overexpression	Triple Negative Breast Cancer	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D
ADAM9 overexpression	Non Small Cell Lung Cancer	ADAM9 overexpression	Non Small Cell Lung Cancer	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D
ADAM9 positive	Solid Tumor	ADAM9 positive	Solid Tumor	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D
ADAM9 expression	Colorectal Cancer	ADAM9 expression	Colorectal Cancer	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D	IMGC936 Sensitive: D – Preclinical IMGC936 Sensitive : D